Novo Nordisk has launched its weight-loss drug Wegovy in China after it was approved by local health authorities in June. It ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in ...

Novo Nordisk gained approval for Wegovy in China in June, and will initially target Chinese patients willing to pay ...

Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Wegovy's approval by China's NMPA targets individuals with a BMI of 30+ with related health issues; initial supply will be ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

Novo Nordisk (NVO) is aware of 10 deaths and 100 hospitalizations of people that took copycat versions of its popular drugs ...